Bone Abstracts

Vertebral fractures (VF) defined by morphometric analysis of spine radiographs are the most common complication of osteoporosis. Those that come to medical attention, with symptoms such as back pain and kyphosis are termed clinical vertebral fractures (CVF) and account for significant morbidity and mortality. Although much progress was made in identifying loci for bone mineral density, the genetic determinants of CVF remain unclear. Here we present the initial results from a g...

Objectives: To establish the average bone mineral density (BMD) and bone mineral content (BMC) in young male population from the different ethno-geographical groupsMaterials and methods: Estimations of the calcaneal BMD (g/cm2) and BMC (r), using on ALOKA-5.0 DXA machine among Indian (n=58) and Nigerian (n=72) male students (17–20 years), were done. The anthropometric program included body weight, height, shoulder and th...

Objective: To assess the prevalence of co-morbidities in fracture neck of femur patients.Methodology: Study design: Retrospective cohort study.Setting: District General Hospital in United Kingdom.Study subject: a total of 75 patients with fracture neck of femur from 2012 to 2013 were ascertained for any associated co-morbid conditions by case note study.Results: Out of 75 patients, 61 (...

Objective: To assess the prevalence of post-operative medical and surgical complications among fracture neck of femur patients.Method: Study design: retrospective cohort study.Setting: District General Hospital in UK.Study subject: a total of 75 patients with fracture neck of femur from 2012 to 2013 were ascertained for any post-operative complications by case note study.Results: Out of...

Objectives: To assess the pharmacological management of osteoporosis in a cohort of hospitalized medical in-patients within a Welsh district general hospital.Materials and methods: We collected data using medical records on a structured proforma as a point prevalence study targeting medical inpatients aged fifty and above in an admitted hospital cohort.Results: Out of the 117 patients, 88 (75.21%) of them had greater than three ris...

Objective: Osteocalcin, an osteoblast-derived hormone, is among the most abundant proteins in bone and is involved in the regulation of whole-body metabolism, muscle adaptation, and reproduction. High bone turnover and low bone mass are clinical hallmarks of Osteogenesis Imperfecta (OI), a bone disease mainly caused by mutations in the collagen-I gene. Recently, we have shown that growing mice with a severe dominant form of OI, Col1a1Jrt/+ mice, displayed significantly elevate...

Low levels of 25-hydroxyvitamin D have been documented among inhabitants of the wider Middle East and North African countries. Sunlight has long been recognized as a major provider of vitamin D. In this study we aimed to determine the optimum time for sun exposure in the Central region of Riyadh, Saudi Arabia. Ampoules containing 7-dehydrocholesterol in ethanol were exposed to sunlight every hour starting from sunrise until sunset in July and December. Our results demonstrated...

Background: The development of hypophosphataemic rickets in infants fed with the elemental formula (EF) Neocate® has been recently reported. We present seven cases of exclusively Neocate-fed babies who developed hypophosphataemic rickets.Presenting problem: Three patients (P1,3,4) had incidental findings of rickets on chest X-rays, two (P2,6) developed leg deformities and rickets was confirmed on X-rays, and two (P5,6) presented with femu...

Objectives: X-linked hypophosphataemia (XLH) is a rare inherited form of osteomalacia characterised by low blood phosphate levels which lead to inadequate mineralisation of bone and rickets. Burosumab is an anti-FGF23 fully human monoclonal-antibody, and the first treatment to target the underlying pathophysiology of XLH. Real-world evidence is important in validating the findings of clinical studies. We report relevant real-world biochemical data on children under five years ...

Objectives: X-linked hypophosphataemia (XLH) is a rare inherited form of osteomalacia characterised by low blood phosphate levels which lead to inadequate mineralisation of bone resulting in rickets, skeletal abnormalities, physical impairment, weakness, and pain. Burosumab is an anti-FGF23 fully human monoclonal-antibody, and the first treatment to target the underlying pathophysiology of XLH. Real-world evidence is important in validating the findings of clinical studies. We...